Incidence of nonmelanoma skin cancer in the United States population aged 65 years and older, 2014

Rogers, Howard W.; Beveridge, Mara; Puente, J. L. de la; Wixson, Sarah E.; Loy, Bryan A.; Happe, Laura E.

doi:10.1016/j.jaad.2019.08.079

Cited by 13 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Optum CDM data are collected from patients with private insurance and Medicare Advantage, who likely differ from patients without insurance or with Medicare/Medicaid. 23 How these differences in insurance status could alter the BCC:cSCC ratio is uncertain, but these data are more comprehensive than prior analyses relying on regional [2][3][4] or Medicare-only 1 populations. Second, subclassifications of BCC (eg, nodular, superficial) and cSCC (eg, invasive vs in situ) were not evaluated.…”

Section: Limitationsmentioning

confidence: 99%

Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Defining which populations are affected by basal cell carcinoma (BCC) vs cutaneous squamous cell carcinoma (cSCC) may inform targeted public health strategies. Incidence of BCC and cSCC is not reported to national cancer registries, but claims data for the treatment of BCC and cSCC provide insights into the epidemiology of keratinocyte carcinoma.OBJECTIVE To define differences in the ratio of BCC to cSCC in adults (age, Ն18 years) in a large database of patients with commercial insurance and Medicare Advantage coverage. DESIGN, SETTING, AND PARTICIPANTSThis cross-sectional analysis used deidentified data derived from the Optum Clinformatics Data Mart to perform a retrospective evaluation of a large commercially insured cohort based on treatment claims from January 1, 2012, to December 31, 2016. Patients with a diagnosed and treated BCC or cSCC as determined by codes from the

show abstract

Section: Limitationsmentioning

confidence: 99%

Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Within NMSC there are two primary subcategories: basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). Recent estimates place the number of total NMSCs diagnosed in the US each year at about 5 million 6,7 . BCCs are the most common form of NMSC (∼80% of cases) but rarely metastasize, while cSCCs make up ∼20% of NMSCs, but metastasize at an estimated rate of 2.6%–9% 8,9 .…”

Section: Introduction To Nonmelanoma Skin Cancer and Treatment Optionsmentioning

confidence: 99%

“…Recent estimates place the number of total NMSCs diagnosed in the US each year at about 5 million. 6,7 BCCs are the most common form of NMSC (∼80% of cases) but rarely metastasize, while cSCCs make up ∼20% of NMSCs, but metastasize at an estimated rate of 2.6%-9%. 8,9 Actinic keratoses (AKs) are epidermal keratinocytic dysplasias that can occur in chronically sun-exposed areas of the skin.…”

Section: Introduction To Nonmelanoma Skin Cancer and Treatment Optionsmentioning

confidence: 99%

Review: PD‐L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer

Vaishampayan

Curiel‐Lewandrowski

Dickinson

2022

Molecular Carcinogenesis

View full text Add to dashboard Cite

Recent advances in the understanding and targeting of immune checkpoints have led to great progress in immune therapies against many forms of cancer. While many types of immune checkpoints are currently targeted in the clinic, this review will focus on recent research implicating the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) axis as an emerging focus for the treatment of keratinocytic tumors. PD-L1 is of particular interest in nonmelanoma skin cancer (NMSC), as it is not only upregulated in these tumors but is stimulated by environmental ultraviolet exposure. This response may also make PD-L1 an excellent target for photochemoprevention using topically applied small molecule inhibitors.Here, we summarize recent investigations on PD-L1 expression and clinically relevant immune checkpoint inhibitor treatment in cutaneous squamous cell carcinoma, basal cell carcinoma, and head and neck squamous cell carcinoma, as well as small molecule agents targeting PD-L1 that may be useful for clinical development aiming at treatment or prevention of NMSC.

show abstract

“…utaneous squamous cell carcinoma (CSCC) is a common skin cancer with incidence estimates ranging from approximately 700 000 to more than 1 million cases annually in the US. [1][2][3] Most patients with CSCC are of low risk with an excellent prognosis after surgical clearance using Mohs microsurgery or wide local excision. 4,5 However, a subset of patients with CSCC develops poor outcomes, including recurrence, metastasis, and disease-specific mortality.…”

mentioning

confidence: 99%

Implications of Satellitosis or In-transit Metastasis in Cutaneous Squamous Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

cell carcinoma and melanoma, satellitosis or in-transit metastasis (S-ITM) is not incorporated into the current cutaneous squamous cell carcinoma (CSCC) staging systems. It is important to determine if the clinical outcomes of S-ITM are relevant to prognosis for patients with CSCC.OBJECTIVES To evaluate the association of S-ITM with clinical outcomes in patients with CSCC and to determine its prognostic implications. DESIGN, SETTINGS, AND PARTICIPANTSA dual-institution (Cleveland Clinic and Brigham and Women's Hospital) database was queried for patients who were treated for CSCC in 2010 to 2020. Patients who were node-negative and had S-ITM-the presence of dermal lesions between the primary tumor and first-echelon lymphatic nodal basins at any point in the disease course-were identified. Subcohorts of patients with T3N0 tumors, T4N0 tumors (bone invasive), N1 to 3, and M1 disease were identified for comparison. The American Joint Committee on Cancer staging system was used to define cancer stages. Data were analyzed from January 15 to March 31, 2021. MAIN OUTCOMES AND MEASURESPairwise comparison of CSCC recurrence and disease-specific survival in patients with and without S-ITM was performed using Cox proportional hazard modeling. Kaplan-Meier and Fine-Gray competing risk methods were used to estimate disease-specific survival and CSCC recurrence, respectively. RESULTSIn a total of 518 patients with CSCC, S-ITM was present in 72 (13.9 %) patients (median age [range], 73.9 [31.6-95.8] years; 59 [82%] men; 69 [96%] White non-Hispanic individuals; 25 [35%] patients with immunosuppression) who were node-negative. The subcohorts were composed of 341 patients with T3N0 cancer, 36 with T4N0, 70 with N1 to 3, and 19 with M1 disease. Pairwise comparisons between disease levels using Cox proportional hazard model demonstrated lower cumulative incidence of CSCC recurrence rates in the T3N0 (HR, 0.21; 95% CI, 0.14-0.30; P < .001) and T4N0 (HR, 0.36; 95% CI, 0.19-0.68; P = .001) cohorts compared with the S-ITM cohort. No significant difference was observed between patients who were node-positive and those with S-ITM (HR, 0.74; 95% CI, 0.48-1.14; P = .16). The 5-year disease-specific survival rates were 76% for T3N0, 64% for T4N0, 41% for S-ITM, and 39% for N1 to 3. Compared with the S-ITM cohort, DSS was significantly higher in the T3N0 (HR, 0.23; 95% CI, 0.15-0.35; P < .0001) and T4N0 (HR, 0.37; 95% CI, 0.19-0.76; P = .01) cohorts, and not significantly different in the node-positive (HR, 0.77; 95% CI, 0.84-3.93; P = .30) and metastatic cohorts (HR, 1.81; 95% CI, 0.84-3.93; P = .13).CONCLUSIONS AND RELEVANCE This multi-institutional cohort study found that patients with CSCC and S-ITM appear to have clinical outcomes comparable to those of patients who are node-positive, and an increased risk of recurrence and worse survival compared with patients who have T3 and T4 disease. These outcomes are similar to those observed for Merkel cell carcinoma and melanoma. Given that S-ITM may be a powerful prognostic factor, it should be ...

show abstract

Incidence of nonmelanoma skin cancer in the United States population aged 65 years and older, 2014

Cited by 13 publications

References 2 publications

Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States

Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States

Review: PD‐L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer

Implications of Satellitosis or In-transit Metastasis in Cutaneous Squamous Cell Carcinoma

Contact Info

Product

Resources

About